Boston Scientific (MEX:BSX) EBIT: MXN75,035 Mil (TTM As of Mar. 2026)


MEX:BSX Boston Scientific Corp MEX:BSX
83 GF Score
Price MXN790.00
GF Value MXN1,849.68
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is Boston Scientific EBIT?

Boston Scientific MEX:BSX 83 EBIT is MXN75,035 Mil as of Mar. 2026. GuruFocus rates MEX:BSX with a GF Score™ of 83/100 and a GF Value™ of MXN1,849.68 (Significantly Undervalued). The stock has 1 warning sign investors should review.

Boston Scientific's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was MXN22,577 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was MXN75,035 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Boston Scientific's annualized ROC % for the quarter that ended in Mar. 2026 was 11.20%. Boston Scientific's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 80.26%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Boston Scientific's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 5.64%.


Boston Scientific  (MEX:BSX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Boston Scientific's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=77324.216 * ( 1 - 0% )/( (672746.969 + 707657.246)/ 2 )
=77324.216/690202.1075
=11.20 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=786362.937 - 78234.767 - ( 35381.201 - max(0, 97933.002 - 158342.126+35381.201))
=672746.969

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=799768.278 - 65909.519 - ( 26201.513 - max(0, 82427.472 - 156595.967+26201.513))
=707657.246

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Boston Scientific's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=90307.76/( ( (72653 + max(30411.627, 0)) + (73266.86 + max(48706.323, 0)) )/ 2 )
=90307.76/( ( 103064.627 + 121973.183 )/ 2 )
=90307.76/112518.905
=80.26 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(52684.678 + 52990.775 + 17285.472) - (78234.767 + 5635.784 + 8678.747)
=30411.627

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(54584.983 + 56207.926 + 19601.545) - (65909.519 + 0 + 15778.612)
=48706.323

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Boston Scientific's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=75035.497/1331151.317
=5.64 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Boston Scientific EBIT Related Terms


Boston Scientific EBIT Historical Data

* Premium members only.

The historical data trend for Boston Scientific's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Boston Scientific EBIT Chart

Boston Scientific Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29,068.34 31,408.06 38,192.06 53,953.70 67,233.28

Boston Scientific Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18,146.42 19,412.91 18,821.15 14,224.50 22,576.94

MEX:BSX vs EW, MDT, DXCM: EBIT Comparison

For the Medical Devices subindustry, Boston Scientific's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Boston Scientific EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Boston Scientific's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Boston Scientific's EV-to-EBIT falls into.


MEX:BSX
83GF Score
Boston Scientific Corp MEX:BSX
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Boston Scientific EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN75,035 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of MXN75,035 Mil mean?
Boston Scientific (MEX:BSX) has a EBIT of MXN75,035 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Boston Scientific.
Is Boston Scientific's EBIT too high?
Boston Scientific's current EBIT is MXN75,035 Mil. Overall, Boston Scientific has a GF Score™ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Boston Scientific's EBIT compare to EW and MDT?
Boston Scientific's EBIT of MXN75,035 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Boston Scientific. Boston Scientific's current EBIT is MXN75,035 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boston Scientific stock overvalued right now?
Based on GuruFocus' analysis, Boston Scientific (MEX:BSX) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN1,849.68, compared to a current price of MXN790.00 — trading 57.3% below its estimated fair value. The current EBIT is MXN75,035 Mil. Boston Scientific's overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Boston Scientific (MEX:BSX), the current EBIT is MXN75,035 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Boston Scientific (MEX:BSX) Overvalued in 2026?

Based on GuruFocus' analysis, Boston Scientific stock appears to be undervalued. The current stock price of MXN790.00 is trading 57.3% below its estimated GF Value™ of MXN1,849.68. GuruFocus considers Boston Scientific to be Significantly Undervalued.

Key valuation signals for MEX:BSX:

  • EBIT: MXN75,035 Mil
  • GF Value™: MXN1,849.68 vs. price of MXN790.00 (57.3% below fair value)
  • GF Score™: 83/100 with 1 warning sign

No single metric tells the full story. See the MEX:BSX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Boston Scientific Business Description

Address 300 Boston Scientific Way, Marlborough, MA, USA, 01752-1234
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
83GF Score

Get the complete analysis for MEX:BSX

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN790.00
Price
MXN1,849.68
GF Value